Increasing Equity in Lung Cancer Screening
Conditions: Lung Cancer Interventions: Behavioral: ED-LCS Sponsors: Indiana University; Eskenazi Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
Conditions: Non-small-cell Lung Cancer (NSCLC) Interventions: Drug: Tislelizumab; Drug: Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC); Drug: Carboplatin or Cisplatin; Procedure: Surgery Sponsors: The Affiliated Hospital of Qingdao University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Conditions: Non-Small Cell Lung Cancer Interventions: Drug: Datopotamab Deruxtecan; Drug: Rilvegostomig; Drug: Pembrolizumab Sponsors: AstraZeneca; Daiichi Sankyo Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
Conditions: Carcinoma; Non-small Cell Lung Cancer Interventions: Procedure: Blood ctDNA + methylation + PET-CT and Postoperative pathology; Procedure: MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNA; Procedure: Intraoperative lymph node dissection Sponsors: Shanghai Chest Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
Conditions: Non-small Cell Lung Cancer Interventions: Drug: sunvozertinib in combination with Anlotinib Sponsors: Hunan Province Tumor Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Enhancing Lung Cancer Screening Through Human-Centered Intervention
Conditions: Lung Cancer Interventions: Behavioral: Pre-Visit Planner; Behavioral: Pre-Visit Planner + MyChart Sponsors: University of California, Davis Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
Conditions: EGF-R Positive Non-Small Cell Lung Cancer; CNS Metastases Interventions: Drug: Furmonertinib Sponsors: Tang-Du Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
To Evaluate the Efficacy and Safety of Anrotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
Conditions: Event-free Lifetime Interventions: Drug: Anlotinib Sponsors: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ( " FDA " ) has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line treatment for patients with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 7, 2024 Category: Pharmaceuticals Source Type: clinical trials
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: Osimertinib; Drug: Datopotamab Deruxtecan Sponsors: AstraZeneca; Daiichi Sankyo Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
Conditions: Metastatic Cancer; NSCLC Stage IV; Non-small Cell Lung Cancer Stage IV; Small Cell Lung Cancer Metastatic; Solid Tumor; Clear Cell Renal Cell Carcinoma Metastatic; Urothelial Carcinoma Bladder; Cutaneous Malignant Melanoma; Castration-resistant Prostate Cancer; Prostate Cancer Metastatic; TNBC - Triple-Negative Breast Cancer; Breast Cancer Stage IV; Colon Cancer Stage IV; MSI-H Cancer; Cervical Cancer Stage IV; Endometrial Cancer Stage IV; Mismatch Repair-Deficient Endometrial Endometrioid Adenocarcinoma Interventions: Procedure: Biospecimen Collection; Procedure: Tissue Collection Sponsors: Mayo Clinic Not yet...
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Procedure: Radical resection Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants
Conditions: Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation; Healthy Volunteers Interventions: Drug: BAY2927088; Drug: Itraconazole; Drug: Carbamazepine Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
Conditions: Small Cell Lung Cancer Extensive Stage Interventions: Drug: α-PD-L1/4-1BB DLL3 CAR-T (BHP01) Sponsors: Sichuan University; Chengdu Brilliant Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
The Black Health Block Quit and Screen Project
Conditions: Knowledge; Attitudes; Behavioral Intention Interventions: Other: Black Health Block Culturally Tailored training; Other: Health Disparities and Lung Cancer Screening training Sponsors: University of Arkansas; Virginia Commonwealth University; Coalition for a Tobacco Free Arkansas; National Institute on Minority Health and Health Disparities (NIMHD); National Medical Association Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
